Trial reportProceedings of the National Academy of Sciences of the United States of America1995
Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma.
Trial report in Proceedings of the National Academy of Sciences of the United States of America, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 91 citations in OpenAlex.
- Can repeated plasma donation by asymptomatic HIV-infected individuals delay the onset of AIDS?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 1997Trial
- Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV - a review.AIDS research and therapy · 2025Review
- Review
- Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic.Frontiers in public health · 2021Review
- Convalescent Plasma Therapy for COVID-19: State of the Art.Clinical microbiology reviews · 2020Review
- Antibody-mediated prevention and treatment of HIV-1 infection.Retrovirology · 2018Review
- Broadly neutralizing antibodies in HIV-1 treatment and prevention.Therapeutic advances in vaccines and immunotherapy · 2018Review
- Broadly Neutralizing Antibodies for HIV Eradication.Current HIV/AIDS reports · 2016Review
- Ebola virus convalescent blood products: where we are now and where we may need to go.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2014Review
- Postconditioning hormesis put in perspective: an overview of experimental and clinical studies.Dose-response : a publication of International Hormesis Society · 2011Article
- Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain.Blood · 2009Article
- Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.Expert opinion on biological therapy · 2009Review
- Therapeutic antibodies: current state and future trends--is a paradigm change coming soon?Methods in molecular biology (Clifton, N.J.) · 2009Article
- The growth and potential of human antiviral monoclonal antibody therapeutics.Nature biotechnology · 2007Review
- Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.Journal of virology · 2004Article
- Back to the future: antibody-based strategies for the treatment of infectious diseases.Molecular biotechnology · 2002Review
- Passive immunity in prevention and treatment of infectious diseases.Clinical microbiology reviews · 2000Review
- A vaccine for HIV type 1: the antibody perspective.Proceedings of the National Academy of Sciences of the United States of America · 1997Review
- Immunity to retroviral infection: the Friend virus model.Proceedings of the National Academy of Sciences of the United States of America · 1997Review
- Passive immunotherapy for retroviral disease: influence of major histocompatibility complex type and T-cell responsiveness.Proceedings of the National Academy of Sciences of the United States of America · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A randomized double-blind controlled trial was conducted to determine the efficacy of passive immunotherapy in the treatment of symptomatic human immunodeficiency virus (HIV) infection. This trial included 86 symptomatic patients randomized to receive plasma rich in anti-HIV-1 antibody or standard seronegative plasma. Each patient in both groups received a 300-ml infusion every 14 days over a 1-year period, and every 28 days thereafter, in addition to zidovudine and other conventional prophylactic treatments. Plasma donors were selected among symptomless seropositive individuals with a CD4 lymphocyte count > or = 400 x 10(6) cells per liter, a negative p24 antigen assay, and a high concentration of anti-p24 antibody. The plasmas were heat-inactivated before infusion. During the study period (day 28-day 365) scheduled by the protocol, clinical benefit from passive immunotherapy was observed in delaying the appearance of the first AIDS-defining event (P < 0.009) and reducing the cumulative incidence of such events, which was estimated 3-fold higher in the control group compared to the treatment group. Seven deaths occurred in the treatment group vs. 11 in the control group (P = 0.27). A total of 47 patients died or exhibited new AIDS-defining events, 18 in the treatment group and 29 in the control group (P = 0.009). No clinical benefit was observed after the 1-year period with infusions performed every 4 weeks. These results indicate a favorable effect of passive immunotherapy on the evolution of advanced AIDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.